Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. (NYSE: MED) generates a steady flow of news centered on its health and wellness programs, metabolic health strategy, and financial performance. As the company behind the OPTAVIA® lifestyle system and the Metabolic Synchronization™ framework, Medifast regularly issues updates that highlight how it is addressing obesity, lifestyle change, and the broader challenge of metabolic dysfunction.
Readers of this MED news page can expect coverage of quarterly and annual financial results, including trends in revenue, the number of independent active earning OPTAVIA coaches, and revenue per active earning coach. These releases often include commentary from leadership on business transformation, strategic priorities, and the company’s focus on metabolic health and long-term growth.
Medifast also publishes scientific and clinical news, such as research presented at conferences like ObesityWeek. These updates describe studies on topics including lean mass preservation on the Optimal Weight 5 & 1 Plan®, the long-term effects of anti-obesity medications, and links between sleep quality and metabolic outcomes. Such items illustrate how the company’s Scientific & Clinical Affairs team and Scientific Advisory Board contribute to evidence-based program development.
In addition, investors and observers will find corporate and strategic announcements, including the introduction of Metabolic Synchronization™, shifts in positioning from weight loss to metabolic health, and leadership or governance changes documented in press releases and related SEC filings. The company also highlights brand and educational initiatives, such as the “Health by Design” docuseries that explores cultural and environmental factors influencing metabolic health and longevity.
This news page is a central resource for following Medifast’s evolving approach to metabolic health, its OPTAVIA coach network, research milestones, and key corporate developments. For those tracking MED, it offers a consolidated view of how the company communicates its strategy, science, and financial trajectory over time.
Summary not available.
Medifast (NYSE: MED) reported Q3 2022 results, revealing a revenue decline of 5.6% to $390.4 million compared to Q3 2021. Active earning OPTAVIA Coaches increased by 8.5% to 66,200, but average revenue per coach fell by 12.9% to $5,897. Net income decreased to $36.2 million, or $3.27 per diluted share. The company announced a quarterly cash dividend of $1.64 per share and ended the quarter with $69.7 million in cash and no debt. Full-year revenue guidance was revised down to $1.51 billion to $1.59 billion due to inflation and acquisition challenges.
Medifast (NYSE: MED) announced that its OPTA VIA Program was recognized as the #1 Weight Loss Program in the U.S. by revenue for 2021, according to Euromonitor International. The program focuses on holistic health, impacting over two million lives and achieving a revenue increase of 455% over five years, from $501 million in 2018 to $1.526 billion in 2021. Medifast's independent coaches supported over one million clients in the past year. The company will announce its Q3 2022 financial results on November 3, 2022.
Summary not available.
Medifast (NYSE: MED) will announce its third quarter financial results for the period ending September 30, 2022 on November 3, 2022, after market close. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, hosted by CEO Dan Chard and CFO Jim Maloney. Investors can join the call via the company’s website or by telephone. A playback of the call will be available until November 10, 2022. Medifast is recognized as a leader in the U.S. weight management industry, valued at $7 billion.
Medifast (NYSE: MED) has launched the "Healthy Habits For All" curriculum in partnership with WeAreTeachers, aiming to promote health education among students nationwide. Designed for grades K-5, the curriculum focuses on essential health topics such as nutrition, physical activity, and mental well-being. It is accessible to millions of teachers, with a priority on under-resourced communities. Medifast projects the program will reach over 20,000 students in 700 school districts across all 50 states. This initiative aligns with Medifast's commitment to improving public health through education.
Medifast (NYSE: MED) declared a $1.64 quarterly cash dividend, payable on November 8, 2022, to stockholders of record as of September 20, 2022. The company aims to sustain a quarterly dividend program, contingent on its Board of Directors' discretion. Medifast is a leader in the U.S. weight management market, valued at $7 billion, helping over 2 million customers through its OPTAVIA® community. This dividend announcement underscores Medifast's financial health and commitment to returning value to shareholders.
Medifast, Inc. (NYSE: MED) announced that CEO Dan Chard and CFO Jim Maloney will participate in a fireside chat at the Jefferies Virtual Fitness & Wellness Summit on September 12, 2022. A webcast of this event will be accessible on Medifast's Investor Relations website starting at 9:00am ET and will remain available for about 30 days. Medifast, recognized as a leader in the health and wellness sector, offers OPTAVIA®, a comprehensive weight management solution. The company emphasizes lifelong transformation through healthy habits.
Medifast (NYSE: MED) reported a 15.0% increase in revenue to $453.3 million for Q2 2022, driven by a 14.9% rise in active earning OPTAVIA Coaches to 68,000. However, net income decreased 16.7% to $39.1 million, leading to an EPS of $3.42, down 13.6%. The company announced a $100 million accelerated share repurchase program and plans to pay a quarterly cash dividend of $1.64 per share. Due to macroeconomic pressures, Medifast revised its full-year revenue guidance down to $1.58 billion - $1.66 billion and EPS to $12.70 - $14.10.
Medifast (NYSE: MED) hosted its annual OPTAVIA Convention from July 21-23, 2022, in Atlanta, attracting over 17,000 attendees, marking the largest event to date. The company reported significant growth, becoming the top weight loss program in the U.S. by revenue in 2021. Medifast aims to expand its presence in the $230 billion health market, with CEO Dan Chard stating they've served more clients than ever. The event included keynote speakers and raised over $90,000 for charity, emphasizing their commitment to community and health transformation.